UA115527C2 - Застосування n-(4-{[6,7-бic(мeтилoкcи)xiнoлiн-4-iл]oкcи}фeнiл)-n'-(4-фтopфeнiл)циклoпpoпaн-1,1-дикapбoкcaмiду для лікування нирково-клітинної карциноми (варіанти) - Google Patents
Застосування n-(4-{[6,7-бic(мeтилoкcи)xiнoлiн-4-iл]oкcи}фeнiл)-n'-(4-фтopфeнiл)циклoпpoпaн-1,1-дикapбoкcaмiду для лікування нирково-клітинної карциноми (варіанти)Info
- Publication number
- UA115527C2 UA115527C2 UAA201313886A UAA201313886A UA115527C2 UA 115527 C2 UA115527 C2 UA 115527C2 UA A201313886 A UAA201313886 A UA A201313886A UA A201313886 A UAA201313886 A UA A201313886A UA 115527 C2 UA115527 C2 UA 115527C2
- Authority
- UA
- Ukraine
- Prior art keywords
- cancer
- bone
- pain
- treating
- directed
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Abstract
Винахід стосується застосування N-(4-{[6,7-бic(мeтилoкcи)xiнoлiн-4-iл]oкcи}фeнiл)-N'-(4-фтopфeнiл)циклoпpoпaн-1,1-дикapбoкcaмiду або його малатної солі один раз на день у вигляді таблетки, що містить 60, 40 або 20 мг N-(4-{[6,7-бic(мeтилoкcи)xiнoлiн-4-iл]oкcи}фeнiл)-N'-(4-фтopфeнiл)циклoпpoпaн-1,1-дикapбoкcaмiду, для лікування метастазів в кістці у пацієнта з нирково-клітинною карциномою; застосування N-(4-{[6,7-бic(мeтилoкcи)xiнoлiн-4-iл]oкcи}фeнiл)-N'-(4-фтopфeнiл)циклoпpoпaн-1,1-дикapбoкcaмiду або його малатної солі для зменшення або стабілізації метастатичних уражень кістки, пов’язаних з нирково-клітинною карциномою; застосування N-(4-{[6,7-бic(мeтилoкcи)xiнoлiн-4-iл]oкcи}фeнiл)-N'-(4-фтopфeнiл)циклoпpoпaн-1,1-дикapбoкcaмiду або його малатної солі для ослаблення болю в кістці через метастатичні ураження кістки, пов’язані з нирково-клітинною карциномою; застосування N-(4-{[6,7-бic(мeтилoкcи)xiнoлiн-4-iл]oкcи}фeнiл)-N'-(4-фтopфeнiл)циклoпpoпaн-1,1-дикapбoкcaмiду або його малатної солі для збільшення загальної виживаності у пацієнтів з нирково-клітинною карциномою, яка метастазувала в кістку.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161481682P | 2011-05-02 | 2011-05-02 | |
US201161557366P | 2011-11-08 | 2011-11-08 | |
PCT/US2012/036191 WO2012151326A1 (en) | 2011-05-02 | 2012-05-02 | Method of treating cancer and bone cancer pain |
Publications (1)
Publication Number | Publication Date |
---|---|
UA115527C2 true UA115527C2 (uk) | 2017-11-27 |
Family
ID=46062768
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA201313886A UA115527C2 (uk) | 2011-05-02 | 2012-05-02 | Застосування n-(4-{[6,7-бic(мeтилoкcи)xiнoлiн-4-iл]oкcи}фeнiл)-n'-(4-фтopфeнiл)циклoпpoпaн-1,1-дикapбoкcaмiду для лікування нирково-клітинної карциноми (варіанти) |
Country Status (16)
Country | Link |
---|---|
US (3) | US20140179736A1 (uk) |
EP (1) | EP2704717A1 (uk) |
JP (4) | JP2014513129A (uk) |
KR (1) | KR20140025496A (uk) |
CN (1) | CN103717221A (uk) |
AR (1) | AR086242A1 (uk) |
AU (2) | AU2012250759B2 (uk) |
BR (1) | BR212013028314U2 (uk) |
CA (1) | CA2834778C (uk) |
EA (1) | EA029506B1 (uk) |
GE (1) | GEP201706678B (uk) |
IL (1) | IL229094A0 (uk) |
MX (1) | MX2013012695A (uk) |
TW (2) | TW201806598A (uk) |
UA (1) | UA115527C2 (uk) |
WO (1) | WO2012151326A1 (uk) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112013000980B1 (pt) | 2010-07-16 | 2022-08-16 | Exelixis, Inc | Composições farmacêuticas moduladoras de c-met |
DK2621481T4 (da) | 2010-09-27 | 2023-01-09 | Exelixis Inc | Dobbelte inhibitorer af MET og VEGF til behandling af kastrationsresistent prostatacancer og osteoblastiske knoglemetastaser |
JP2014505109A (ja) | 2011-02-10 | 2014-02-27 | エクセリクシス, インク. | キノリン化合物およびそのような化合物を含有する医薬組成物の調製方法 |
US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
TW201806598A (zh) | 2011-05-02 | 2018-03-01 | 艾克塞里克斯公司 | 治療癌症及骨癌疼痛之方法 |
BR112014006702A2 (pt) * | 2011-09-22 | 2017-06-13 | Exelixis Inc | método para tratar osteoporose |
DK2768796T3 (da) | 2011-10-20 | 2020-02-24 | Exelixis Inc | Fremgangsmåde til fremstilling af quinolin-derivater |
JP2015515988A (ja) | 2012-05-02 | 2015-06-04 | エクセリクシス, インク. | 溶骨性骨転移を治療するためのmet−vegf二重調節剤 |
US10273211B2 (en) | 2013-03-15 | 2019-04-30 | Exelixis, Inc. | Metabolites of N-{4-([6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
ES2927651T3 (es) | 2013-04-04 | 2022-11-10 | Exelixis Inc | Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer |
KR102354963B1 (ko) | 2014-02-14 | 2022-01-21 | 엑셀리시스, 인코포레이티드 | N-{4-[(6,7-다이메톡시퀴놀린-4-일)옥시]페닐}-n'-(4-플루오로페닐) 사이클로프로판-1,1-다이카복스아마이드의 결정질 고체 형태, 제조 방법 및 사용 방법 |
JP6666849B2 (ja) | 2014-03-17 | 2020-03-18 | エグゼリクシス, インコーポレイテッド | カボザンチニブ製剤の投与 |
CN104788372B (zh) * | 2014-07-25 | 2018-01-30 | 上海圣考医药科技有限公司 | 一种氘代卡博替尼衍生物、其制备方法、应用及其中间体 |
ES2929888T3 (es) | 2014-07-31 | 2022-12-02 | Exelixis Inc | Procedimiento para preparar cabozantinib marcado con flúor 18 y sus análogos |
CN106573042A (zh) | 2014-08-05 | 2017-04-19 | 埃克塞里艾克西斯公司 | 治疗多发性骨髓瘤的药物组合 |
WO2017181187A1 (en) | 2016-04-15 | 2017-10-19 | Exelixis, Inc. | Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate |
JP7166292B2 (ja) | 2017-05-26 | 2022-11-07 | エグゼリクシス, インコーポレイテッド | N-{4-[(6,7-ジメトキシキノリン-4-イル)オキシ]フェニル}-n’-(4-フルオロフェニル)シクロプロパン-1,1-ジカルボキサミドの塩の結晶性固体形態、製造プロセス、及び使用方法 |
US11504362B2 (en) | 2017-06-09 | 2022-11-22 | Exelixis, Inc. | Liquid dosage forms to treat cancer |
JP7177829B2 (ja) * | 2017-09-28 | 2022-11-24 | チョンチン ファーマシューティカル インダストリアル リサーチ インスティテュート カンパニー リミティド | キノリン誘導体およびチロシンキナーゼ阻害剤としてのそれらの応用 |
KR20200115582A (ko) | 2018-01-26 | 2020-10-07 | 엑셀리시스, 인코포레이티드 | 키나제-의존성 장애의 치료용 화합물 |
CN109620143A (zh) * | 2018-11-22 | 2019-04-16 | 张程程 | 调节骨转移中破骨细胞活化机制的测定方法 |
US20230212122A1 (en) * | 2020-05-26 | 2023-07-06 | The Regents Of The University Of Michigan | Mitochondrial targeting compounds for the treatment of associated diseases |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4420565B2 (ja) | 1998-08-21 | 2010-02-24 | 悦郎 尾形 | 悪性腫瘍の骨転移を判定する方法 |
EP1673085B1 (en) | 2003-09-26 | 2011-11-09 | Exelixis, Inc. | C-met modulators and methods of use |
JP5368701B2 (ja) | 2004-07-02 | 2013-12-18 | エクセリクシス、インコーポレイテッド | c−Metモジュレーター及び使用方法 |
WO2006108059A1 (en) | 2005-04-06 | 2006-10-12 | Exelixis, Inc. | C-met modulators and methods of use |
EP2101759B1 (en) * | 2006-12-14 | 2018-10-10 | Exelixis, Inc. | Methods of using mek inhibitors |
UY31800A (es) * | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
AR075084A1 (es) | 2008-09-26 | 2011-03-09 | Smithkline Beecham Corp | Metodo de preparacion de quinolinil -oxidifenil - ciclopropanodicarboxamidas e intermediarios correspondientes |
US20110229469A1 (en) * | 2008-10-01 | 2011-09-22 | Ludwig Institute For Cancer Research | Methods for the treatment of cancer |
CA2743416A1 (en) | 2008-11-13 | 2010-05-20 | Exelixis Inc. | Methods of preparing quinoline derivatives |
TW201028383A (en) | 2008-12-04 | 2010-08-01 | Exelixis Inc | Methods of preparing quinoline derivatives |
KR101733773B1 (ko) | 2009-01-16 | 2017-05-10 | 엑셀리시스, 인코포레이티드 | N-(4-{〔6,7-비스(메틸옥시)퀴놀린-4-일〕옥시}페닐)-n'-(4-플루오로페닐)사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형 |
BR112012001118A2 (pt) | 2009-07-17 | 2016-02-23 | Exelixis Inc | formas cristalinas de n-[3-flúor-4-({6-(metilóxi)-7-[(3-morfolin-4-ilpropil)óxi]-quinolin-4-il}óxi)fenil]-n'-(4-fluorfenil)ciclopropano-1,1-dicarboxamida, composição farmacêutica com as mesmas, métodos de preparação das mesmas e tratamento de câncer |
UA108618C2 (uk) * | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
WO2011112896A1 (en) | 2010-03-12 | 2011-09-15 | Exelixis, Inc | Hydrated crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
US20120070368A1 (en) | 2010-04-16 | 2012-03-22 | Exelixis, Inc. | Methods of Using C-Met Modulators |
EP2593091A1 (en) | 2010-07-16 | 2013-05-22 | Exelixis, Inc. | C-met modulator pharmaceutical compositions |
BR112013000980B1 (pt) * | 2010-07-16 | 2022-08-16 | Exelixis, Inc | Composições farmacêuticas moduladoras de c-met |
JP2012042811A (ja) * | 2010-08-20 | 2012-03-01 | Sony Corp | ズームレンズ及び撮像装置 |
DK2621481T4 (da) | 2010-09-27 | 2023-01-09 | Exelixis Inc | Dobbelte inhibitorer af MET og VEGF til behandling af kastrationsresistent prostatacancer og osteoblastiske knoglemetastaser |
CA2812744A1 (en) | 2010-09-27 | 2012-04-05 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases |
JP2013540759A (ja) | 2010-09-27 | 2013-11-07 | エクセリクシス, インク. | 去勢抵抗性前立腺癌および造骨性転移の治療のためのmetおよびvegfの二元阻害薬 |
WO2012064967A2 (en) * | 2010-11-10 | 2012-05-18 | Cedars-Sinai Medical Center | Cancer cell-derived receptor activator of the nf-kb ligand drives bone and soft tissue metastases |
CN103327979A (zh) | 2010-11-22 | 2013-09-25 | 葛兰素史密斯克莱知识产权(第2号)有限公司 | 治疗癌症的方法 |
JP2014505109A (ja) | 2011-02-10 | 2014-02-27 | エクセリクシス, インク. | キノリン化合物およびそのような化合物を含有する医薬組成物の調製方法 |
US20120252840A1 (en) | 2011-04-04 | 2012-10-04 | Exelixis, Inc. | Method of Treating Cancer |
TW201806598A (zh) | 2011-05-02 | 2018-03-01 | 艾克塞里克斯公司 | 治療癌症及骨癌疼痛之方法 |
TW201306842A (zh) | 2011-06-15 | 2013-02-16 | Exelixis Inc | 使用pi3k/mtor吡啶並嘧啶酮抑制劑及苯達莫司汀及/或利妥昔單抗治療惡性血液疾病之組合療法 |
BR112014006702A2 (pt) | 2011-09-22 | 2017-06-13 | Exelixis Inc | método para tratar osteoporose |
DK2768796T3 (da) | 2011-10-20 | 2020-02-24 | Exelixis Inc | Fremgangsmåde til fremstilling af quinolin-derivater |
US20140323522A1 (en) | 2011-11-08 | 2014-10-30 | Exelixis, Inc. | Method of Treating Cancer |
JP2015515988A (ja) | 2012-05-02 | 2015-06-04 | エクセリクシス, インク. | 溶骨性骨転移を治療するためのmet−vegf二重調節剤 |
EP3134084B1 (en) | 2014-04-25 | 2021-03-17 | Exelixis, Inc. | Method of treating lung adenocarcinoma |
JP6452498B2 (ja) | 2015-03-03 | 2019-01-16 | キヤノン株式会社 | 液体吐出ヘッドの検査装置、及び液体吐出ヘッド |
WO2017181187A1 (en) | 2016-04-15 | 2017-10-19 | Exelixis, Inc. | Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate |
US20190262330A1 (en) | 2017-12-21 | 2019-08-29 | Exelixis, Inc. | Method of Treating Hepatocellular Carcinoma Using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate |
-
2012
- 2012-05-02 TW TW106118300A patent/TW201806598A/zh unknown
- 2012-05-02 BR BR212013028314U patent/BR212013028314U2/pt active IP Right Grant
- 2012-05-02 AR ARP120101544A patent/AR086242A1/es unknown
- 2012-05-02 US US14/115,236 patent/US20140179736A1/en not_active Abandoned
- 2012-05-02 EP EP12720754.6A patent/EP2704717A1/en not_active Withdrawn
- 2012-05-02 JP JP2014509417A patent/JP2014513129A/ja active Pending
- 2012-05-02 GE GEAP201213300A patent/GEP201706678B/en unknown
- 2012-05-02 CN CN201280026424.4A patent/CN103717221A/zh active Pending
- 2012-05-02 AU AU2012250759A patent/AU2012250759B2/en active Active
- 2012-05-02 UA UAA201313886A patent/UA115527C2/uk unknown
- 2012-05-02 KR KR1020137031635A patent/KR20140025496A/ko not_active Application Discontinuation
- 2012-05-02 EA EA201391604A patent/EA029506B1/ru not_active IP Right Cessation
- 2012-05-02 MX MX2013012695A patent/MX2013012695A/es unknown
- 2012-05-02 WO PCT/US2012/036191 patent/WO2012151326A1/en active Application Filing
- 2012-05-02 TW TW101115623A patent/TWI610918B/zh active
- 2012-05-02 CA CA2834778A patent/CA2834778C/en active Active
-
2013
- 2013-10-27 IL IL229094A patent/IL229094A0/en unknown
-
2016
- 2016-08-16 JP JP2016159543A patent/JP6884528B2/ja active Active
-
2017
- 2017-09-13 AU AU2017228578A patent/AU2017228578A1/en not_active Abandoned
-
2018
- 2018-12-26 JP JP2018243772A patent/JP2019077692A/ja not_active Withdrawn
-
2020
- 2020-02-11 US US16/787,212 patent/US11504363B2/en active Active
-
2021
- 2021-02-04 JP JP2021016486A patent/JP2021088569A/ja active Pending
-
2022
- 2022-10-13 US US17/965,529 patent/US20230149384A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
TW201249800A (en) | 2012-12-16 |
NZ617508A (en) | 2016-04-29 |
WO2012151326A1 (en) | 2012-11-08 |
AU2017228578A1 (en) | 2017-10-05 |
US11504363B2 (en) | 2022-11-22 |
US20140179736A1 (en) | 2014-06-26 |
EA201391604A1 (ru) | 2014-03-31 |
JP2021088569A (ja) | 2021-06-10 |
TWI610918B (zh) | 2018-01-11 |
GEP201706678B (en) | 2017-06-12 |
EA029506B1 (ru) | 2018-04-30 |
EP2704717A1 (en) | 2014-03-12 |
KR20140025496A (ko) | 2014-03-04 |
NZ716805A (en) | 2017-11-24 |
CA2834778C (en) | 2019-08-13 |
BR212013028314U2 (pt) | 2015-11-03 |
TW201806598A (zh) | 2018-03-01 |
MX2013012695A (es) | 2014-03-27 |
CA2834778A1 (en) | 2012-11-08 |
US20200255382A1 (en) | 2020-08-13 |
US20230149384A1 (en) | 2023-05-18 |
AR086242A1 (es) | 2013-11-27 |
IL229094A0 (en) | 2013-12-31 |
JP2017105751A (ja) | 2017-06-15 |
JP6884528B2 (ja) | 2021-06-09 |
AU2012250759A1 (en) | 2013-11-28 |
JP2014513129A (ja) | 2014-05-29 |
CN103717221A (zh) | 2014-04-09 |
JP2019077692A (ja) | 2019-05-23 |
AU2012250759B2 (en) | 2017-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2013012695A (es) | Metodo para el tratamiento del cancer y el dolor por cancer de hueso. | |
PH12015501576A1 (en) | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith | |
MX2013003076A (es) | Terapeuticos contra cancer de mama. | |
EA201490814A1 (ru) | Лечение злокачественной опухоли ингибиторами tor-киназы | |
PH12016502354A1 (en) | Pharmaceutical composition | |
TN2013000227A1 (en) | Use of sigma ligands in bone cancer pain | |
EA201390756A1 (ru) | Модулирующие nk-клетки терапии и способы для лечения гематологических злокачественных заболеваний | |
NZ723971A (en) | Methods and compositions for treating ewings sarcoma family of tumors | |
MX2015007185A (es) | Uso de eribulina en el tratamiento de cancer de pecho. | |
MX371275B (es) | Composiciones derivadas de la quitosana. | |
MY176599A (en) | Treatment of prostate cancer with tor kinase inhibitors | |
MX2013002155A (es) | Compuestos para el tratamiento de cancer. | |
MX2014000150A (es) | Sistemas, metodos y formulaciones para tratamiento de cancer. | |
MX2013006319A (es) | Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k y un inhibidor de mek. | |
MX2017013666A (es) | Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer. | |
MX2016002307A (es) | Tratamiento para el cancer. | |
PH12015501980A1 (en) | Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same | |
TN2014000418A1 (en) | Methods for treating cancer using pi3k inhibitor and mek inhibitor | |
IN2014CN02671A (uk) | ||
PH12014502464A1 (en) | Veliparib in combination with whole brain radiation therapy for the treatment of brain metastases | |
EA201491629A1 (ru) | Способы лечения рака с использованием липоплатина |